English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/135591
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorDomingues, Patricia H.-
dc.contributor.authorGonzález-Tablas, María-
dc.contributor.authorOtero, Álvaro-
dc.contributor.authorSousa, Pablo-
dc.contributor.authorGonçalves, Jesús-
dc.contributor.authorLopes, Maria Celeste-
dc.contributor.authorOrfao, Alberto-
dc.contributor.authorTabernero, María D.-
dc.identifierdoi: 10.18632/oncotarget.3870-
dc.identifiere-issn: 1949-2553-
dc.identifier.citationOncotarget 6(13): 10671-10688 (2015)-
dc.descriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al.-
dc.description.abstractMeningiomas are usually considered to be benign central nervous system tumors; however, they show heterogenous clinical, histolopathological and cytogenetic features associated with a variable outcome. In recent years important advances have been achieved in the identification of the genetic/molecular alterations of meningiomas and the signaling pathways involved. Thus, monosomy 22, which is often associated with mutations of the NF2 gene, has emerged as the most frequent alteration of meningiomas; in addition, several other genes (e.g. AKT1, KLF4, TRAF7, SMO) and chromosomes have been found to be recurrently altered often in association with more complex karyotypes and involvement of multiple signaling pathways. Here we review the current knowledge about the most relevant genes involved and the signaling pathways targeted by such alterations. In addition, we summarize those proposals that have been made so far for classification and prognostic stratification of meningiomas based on their genetic/genomic features.-
dc.description.sponsorshipThis work was partially supported by grants from the Fundação para a Ciência e Tecnologia (PIC/IC/83108/2007, FCT, Portugal), Fondo de Investigaciones Sanitarias (RD12/0036/0048, Instituto de Salud Carlos III (ISCIII/FEDER), Ministerio de Sanidad y Consumo, Madrid, Spain), and Consejeria Sanidad Junta de Castilla y León, Gerencia Regional de Salud: GRS689/A/11, and Proyecto Intramural-IBSAL IB14-05. Patrícia Domingues is partially supported by a grant (SFRH/BD/64799/2009) from FCT. Maria Dolores Tabernero is supported by IECSCYL (Soria, Spain).-
dc.publisherImpact Journals-
dc.relation.isversionofPublisher's version-
dc.titleGenetic/molecular alterations of meningiomas and the signaling pathways targeted-
dc.description.versionPeer Reviewed-
dc.contributor.funderFundação para a Ciência e a Tecnologia (Portugal)-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderMinisterio de Sanidad y Consumo (España)-
dc.contributor.funderInstituto de Investigación Biomédica de Salamanca-
dc.contributor.funderInstituto de Estudios de Ciencias de la Salud de Castilla y León-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Genetic-molecular.pdf1,58 MBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.